Literature DB >> 16971402

Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania.

Gabriele Riedner1, Jim Todd, Mary Rusizoka, Donan Mmbando, Leonard Maboko, Eligius Lyamuya, Oliver Hoffmann, I MacLean, Heiner Grosskurth, Richard Hayes.   

Abstract

OBJECTIVES: To determine trends in the prevalence and aetiological distribution of genital ulcer syndrome (GUS) in a cohort of female bar workers and to assess factors associated with these trends.
METHODS: An open cohort of 600 women at high risk of HIV and sexually transmitted infection (STI) was offered screening and treatment for STI at 3-month intervals. The prevalence of GUS and associated aetiological agents (Herpes simplex virus (HSV), Treponema pallidum and Haemophilus ducreyi) were monitored over 27 months through clinical examination, dry lesion swabbing and multiplex polymerase chain reaction. The effects of HIV status and other factors on the prevalence trends of STI were assessed.
RESULTS: A total of 753 women were recruited into the cohort over 10 examination rounds. At recruitment, the seroprevalence was 67% for HIV and 89% for HSV type 2 (HSV-2). During follow-up, 57% of ulcers had unknown aetiology, 37% were due to genital herpes and 6% to bacterial aetiologies, which disappeared completely in later rounds. The absolute prevalence of genital herpes remained stable at around 2%. The proportion of GUS caused by HSV increased from 22% to 58%, whereas bacterial causes declined. These trends were observed in both HIV-negative and HIV-positive women.
CONCLUSIONS: The changes observed in the frequency and proportional distribution of GUS aetiologies suggest that regular STI screening and treatment over an extended period can effectively reduce bacterial STI and should therefore be sustained. However, in populations with a high prevalence of HSV-2, there remains a considerable burden of genital herpes, which soon becomes the predominant cause of GUS. Given the observed associations between genital herpes and HIV transmission, high priority should be given to the evaluation of potential interventions to control HSV-2 either through a vaccine or through episodic or suppressive antiviral therapy and primary prevention.

Entities:  

Mesh:

Year:  2006        PMID: 16971402      PMCID: PMC2598601          DOI: 10.1136/sti.2006.021287

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  21 in total

1.  Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection.

Authors:  C Y Chen; R C Ballard; C M Beck-Sague; Y Dangor; F Radebe; S Schmid; J B Weiss; V Tshabalala; G Fehler; Y Htun; S A Morse
Journal:  Sex Transm Dis       Date:  2000-01       Impact factor: 2.830

2.  Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study.

Authors:  Eline L Korenromp; Roel Bakker; Sake J De Vlas; N Jamie Robinson; Richard Hayes; J Dik F Habbema
Journal:  Sex Transm Dis       Date:  2002-04       Impact factor: 2.830

3.  Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania.

Authors:  Andwele Mwansasu; Davis Mwakagile; Lars Haarr; Nina Langeland
Journal:  J Clin Virol       Date:  2002-04       Impact factor: 3.168

4.  Idiopathic genital ulcers in women infected with human immunodeficiency virus.

Authors:  J Anderson; R A Clark; D H Watts; M Till; C Arrastia; P Schuman; S E Cohn; M Young; L Bessen; R Greenblatt; M Vogler; S Swindells; P Boyer
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-12-01

5.  Association between HIV-1 infection, the etiology of genital ulcer disease, and response to syndromic management.

Authors:  Prashini Moodley; Patrick D J Sturm; Trusha Vanmali; David Wilkinson; Cathy Connolly; A Willem Sturm
Journal:  Sex Transm Dis       Date:  2003-03       Impact factor: 2.830

6.  Thirteen years HIV-1 sentinel surveillance and indicators for behavioural change suggest impact of programme activities in south-west Tanzania.

Authors:  Brigitte Jordan-Harder; Leonard Maboko; Donan Mmbando; Gabriele Riedner; Elisabeth Nägele; Juan Harder; Volker Küchen; Albert Kilian; Rolf Korte; Frank V Sonnenburg
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

7.  Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania.

Authors:  G Riedner; M Rusizoka; O Hoffmann; F Nichombe; E Lyamuya; D Mmbando; L Maboko; P Hay; J Todd; R Hayes; M Hoelscher; H Grosskurth
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

8.  Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial.

Authors:  Rupert Kaul; Joshua Kimani; Nico J Nagelkerke; Karoline Fonck; Elizabeth N Ngugi; Florence Keli; Kelly S MacDonald; Ian W Maclean; Job J Bwayo; Marleen Temmerman; Allan R Ronald; Stephen Moses
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

9.  Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities.

Authors:  Hinda J Ahmed; Judica Mbwana; Eva Gunnarsson; Karin Ahlman; Chalamilla Guerino; Liselott A Svensson; Fred Mhalu; Teresa Lagergard
Journal:  Sex Transm Dis       Date:  2003-02       Impact factor: 2.830

10.  Vulvar ulcer of unknown etiology in a human immunodeficiency virus-infected woman: response to treatment with zidovudine.

Authors:  J M Covino; W M McCormack
Journal:  Am J Obstet Gynecol       Date:  1990-07       Impact factor: 8.661

View more
  1 in total

1.  Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania.

Authors:  Jim Todd; Gabriele Riedner; Leonard Maboko; Michael Hoelscher; Helen A Weiss; Eligius Lyamuya; David Mabey; Mary Rusizoka; Laurent Belec; Richard Hayes
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.